Purpose The authors aimed to separate Fc N-glycopeptides of disease-specific immunoglobulin G (DSIgG) as personalized biomarkers to distinguish non-small cell lung cancer (NSCLC) from benign lung diseases (BLDs). Experimental design DSIgG from 509 BLDs patients and 477 NSCLC patients was isolated using native polyacrylamide gel electrophoresis and then the Fc glycosylation was determined using mass spectrometry. Results For the patients below 60 years of age, a combination of the glycopeptides ratios with one fucose residue difference of DSIgG1 and DSIgG2 can differentiate NSCLC from BLDs, with area under curve (AUC) values of >0.76, sensitivities of >87%, and specificities of >61%. For the patients above 60 years of age, a combination of the glycopeptides ratios with one monosaccharide residue of DSIgG2 can differentiate NSCLC from BLDs, with AUC values of >0.78, sensitivities of >91%, and specificities of >54%. For the same participants, the commonly used clinical biomarkers have AUC values of 0.5-0.621, sensitivities of 15.8-32.9%, and specificities of 75.7-90.5%. Conclusions These findings indicate that these DSIgG Fc glycoforms are potential personalized biomarkers to differentiate NSCLC from BLDs.
基金编号：2018-I2M-AI-014215751647162127
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|3 区医学
小类|3 区生化研究方法
最新[2025]版：
大类|3 区生物学
小类|3 区生化研究方法
第一作者：
第一作者机构：[1]Chinese Acad Med Sci, Inst Basic Med Sci, Dept Biophys & Struct Biol, Beijing 100005, Peoples R China[2]Peking Union Med Coll, Sch Basic Med, Beijing 100005, Peoples R China
通讯作者：
通讯机构：[1]Chinese Acad Med Sci, Inst Basic Med Sci, Dept Biophys & Struct Biol, Beijing 100005, Peoples R China[*1]Chinese Acad Med Sci, Inst Basic Med Sci, Dept Biophys & Struct Biol, Beijing 100005, Peoples R China[2]Peking Union Med Coll, Sch Basic Med, Beijing 100005, Peoples R China[*2]Peking Union Med Coll, Sch Basic Med, Beijing 100005, Peoples R China
推荐引用方式(GB/T 7714)：
Zhang Dan,Li Xiaoou,Liu Xiaofeng,et al.Disease-Specific IgG Fc Glycosylation Ratios as Personalized Biomarkers to Differentiate Non-Small Cell Lung Cancer from Benign Lung Diseases[J].PROTEOMICS CLINICAL APPLICATIONS.2020,14(1):1900016.doi:10.1002/prca.201900016.
APA：
Zhang, Dan,Li, Xiaoou,Liu, Xiaofeng,Wang, Yanmin,Zhang, Mo...&Li, Zhili.(2020).Disease-Specific IgG Fc Glycosylation Ratios as Personalized Biomarkers to Differentiate Non-Small Cell Lung Cancer from Benign Lung Diseases.PROTEOMICS CLINICAL APPLICATIONS,14,(1)
MLA：
Zhang, Dan,et al."Disease-Specific IgG Fc Glycosylation Ratios as Personalized Biomarkers to Differentiate Non-Small Cell Lung Cancer from Benign Lung Diseases".PROTEOMICS CLINICAL APPLICATIONS 14..1(2020)
